Sign in
4

Changes in Ownership

CRISPR Therapeutics AG Filed Acc 0001193125-26-104480

Chief Executive Officer sold 9,798 shares at $52.80 ($517,334)

  • Chief Executive Officer acquired 19,250 shares (option exercise)

From the SEC's structured data for this filing

Trades in this filing

Kulkarni Samarth · Chief Executive Officer

Table I: Non-derivative

2 lines
Date Transaction Shares Price Value Owned after D/I
2026-03-10 Exercise or conversion : show line 1 in the form +19,250 245,356 D
2026-03-11 Sale : show line 2 in the form −9,798 $52.80 $517,334 235,558 D
Open-market sales · 9,798 sh · avg $52.80 · $517,334

Table II: Derivative

1 line
Date Transaction Shares Owned after D/I
2026-03-10 Exercise or conversion : show line 3 in the form Restricted Stock Units −19,250 19,250 D
Loading xslF345X05/ownership.xml…